Immunovant (IMVT) News Today → My system predicted the BA collapse – now it’s issuing an AI warning (From Chaikin Analytics) (Ad) Free IMVT Stock Alerts $30.48 +0.60 (+2.01%) (As of 05/14/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 12 at 4:47 AM | marketbeat.comVictory Capital Management Inc. Reduces Stock Position in Immunovant, Inc. (NASDAQ:IMVT)Victory Capital Management Inc. lowered its stake in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 12.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 325,534 shares ofMay 8, 2024 | marketbeat.comRussell Investments Group Ltd. Acquires 136,418 Shares of Immunovant, Inc. (NASDAQ:IMVT)Russell Investments Group Ltd. raised its stake in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 337.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 176,901 sharesMay 8, 2024 | americanbankingnews.comImmunovant, Inc. (NASDAQ:IMVT) Receives Consensus Rating of "Buy" from BrokeragesMay 7, 2024 | seekingalpha.comargenx: Innovation Over Losses In Autoimmune ArenaMay 7, 2024 | finance.yahoo.comZacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and LigandMay 7, 2024 | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) Shares Sold by Federated Hermes Inc.Federated Hermes Inc. lessened its position in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 99.2% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,979 shares of the company's stock after selling 356,609 shares during the quarApril 30, 2024 | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) Short Interest UpdateImmunovant, Inc. (NASDAQ:IMVT - Get Free Report) was the target of a large decline in short interest in the month of April. As of April 15th, there was short interest totalling 8,510,000 shares, a decline of 5.7% from the March 31st total of 9,020,000 shares. Based on an average daily volume of 1,150,000 shares, the days-to-cover ratio is currently 7.4 days. Approximately 14.1% of the shares of the company are sold short.April 28, 2024 | investing.comImmunovant CTO sells shares worth over $209k to cover taxesApril 27, 2024 | insidertrades.comImmunovant, Inc. (NASDAQ:IMVT) Insider Sells $94,242.90 in StockApril 27, 2024 | insidertrades.comImmunovant, Inc. (NASDAQ:IMVT) CTO Sells $209,207.10 in StockApril 26, 2024 | marketbeat.comabrdn plc Makes New $13.81 Million Investment in Immunovant, Inc. (NASDAQ:IMVT)abrdn plc purchased a new position in Immunovant, Inc. (NASDAQ:IMVT - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 327,706 shares of the company's stock, valued at approximately $13,806,0April 24, 2024 | finance.yahoo.comShould You Hold Immunovant (IMVT)?April 23, 2024 | marketbeat.comAllspring Global Investments Holdings LLC Acquires 36,659 Shares of Immunovant, Inc. (NASDAQ:IMVT)Allspring Global Investments Holdings LLC increased its holdings in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 590.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 42,865 shares of the company's stoApril 22, 2024 | markets.businessinsider.comBuy Rating Affirmed for Immunovant on Strong Drug Development Prospects and Efficacy ConfidenceApril 21, 2024 | insidertrades.comJulia G. Butchko Sells 10,115 Shares of Immunovant, Inc. (NASDAQ:IMVT) StockApril 20, 2024 | investing.comImmunovant CFO sells shares worth over $350kApril 19, 2024 | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) Insider Sells $293,941.90 in StockImmunovant, Inc. (NASDAQ:IMVT - Get Free Report) insider Julia G. Butchko sold 10,115 shares of the business's stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $29.06, for a total transaction of $293,941.90. Following the transaction, the insider now owns 451,627 shares in the company, valued at approximately $13,124,280.62. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.April 17, 2024 | marketbeat.comImmunovant (NASDAQ:IMVT) Trading Down 3.6%Immunovant (NASDAQ:IMVT) Trading Down 3.6%April 16, 2024 | finance.yahoo.comImmunovant, Inc. (IMVT) Stock Historical Prices & Data - Yahoo FinanceApril 15, 2024 | marketbeat.comWCM Investment Management LLC Takes $4.55 Million Position in Immunovant, Inc. (NASDAQ:IMVT)WCM Investment Management LLC acquired a new stake in Immunovant, Inc. (NASDAQ:IMVT - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 107,401 shares of the company's stock, valued at apprApril 15, 2024 | nasdaq.comImmunovant is Now Oversold (IMVT)April 12, 2024 | investing.comImmunovant CEO sells over $149,000 in company stockApril 11, 2024 | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) Expected to Post Q1 2026 Earnings of ($0.49) Per ShareImmunovant, Inc. (NASDAQ:IMVT - Free Report) - Stock analysts at Zacks Research dropped their Q1 2026 earnings per share (EPS) estimates for Immunovant in a research note issued on Monday, April 8th. Zacks Research analyst E. Bagri now anticipates that the company will post earnings per share ofApril 11, 2024 | insidertrades.comImmunovant, Inc. (NASDAQ:IMVT) Insider Julia G. Butchko Sells 1,053 SharesApril 10, 2024 | marketbeat.comJulia G. Butchko Sells 1,053 Shares of Immunovant, Inc. (NASDAQ:IMVT) StockImmunovant, Inc. (NASDAQ:IMVT - Get Free Report) insider Julia G. Butchko sold 1,053 shares of the business's stock in a transaction that occurred on Tuesday, April 9th. The stock was sold at an average price of $31.18, for a total value of $32,832.54. Following the completion of the transaction, the insider now owns 461,742 shares in the company, valued at approximately $14,397,115.56. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.April 8, 2024 | marketbeat.comImmunovant (NASDAQ:IMVT) Stock Price Down 2.8%Immunovant (NASDAQ:IMVT) Stock Price Down 2.8%April 4, 2024 | seekingalpha.comImmunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)April 2, 2024 | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) Sees Significant Increase in Short InterestImmunovant, Inc. (NASDAQ:IMVT - Get Free Report) was the target of a significant increase in short interest in March. As of March 15th, there was short interest totalling 9,350,000 shares, an increase of 7.7% from the February 29th total of 8,680,000 shares. Approximately 15.3% of the company's stock are short sold. Based on an average daily volume of 1,320,000 shares, the short-interest ratio is presently 7.1 days.April 1, 2024 | marketbeat.com121,268 Shares in Immunovant, Inc. (NASDAQ:IMVT) Acquired by Assenagon Asset Management S.A.Assenagon Asset Management S.A. bought a new position in Immunovant, Inc. (NASDAQ:IMVT - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 121,268 shares of the company's stock, valued at approxMarch 30, 2024 | marketbeat.comSG Americas Securities LLC Reduces Stake in Immunovant, Inc. (NASDAQ:IMVT)SG Americas Securities LLC trimmed its holdings in Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 69.0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 29,937 shares of the company's stock after sellingMarch 26, 2024 | marketbeat.comWellington Management Group LLP Makes New Investment in Immunovant, Inc. (NASDAQ:IMVT)Wellington Management Group LLP purchased a new position in Immunovant, Inc. (NASDAQ:IMVT - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 168,608 shares of the company's stock, valued at approximately $March 25, 2024 | investorplace.comWall Street's Favorite Biotech Stocks? 3 Names That Could Make You Filthy RichMarch 25, 2024 | marketbeat.comImmunovant (NASDAQ:IMVT) Given "Buy" Rating at Truist FinancialTruist Financial reiterated a "buy" rating and issued a $48.00 target price on shares of Immunovant in a research note on Monday.March 22, 2024 | markets.businessinsider.comBuy Rating for Immunovant Amidst Strong Market Position and Promising Batoclimab TrialsMarch 21, 2024 | marketbeat.comImmunovant (NASDAQ:IMVT) Shares Gap Up to $31.57Immunovant (NASDAQ:IMVT) Shares Gap Up to $31.57March 16, 2024 | marketbeat.comCitigroup Inc. Buys 38,179 Shares of Immunovant, Inc. (NASDAQ:IMVT)Citigroup Inc. grew its stake in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 43.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 126,316 shares of the company's stock after buying an additioMarch 13, 2024 | marketbeat.comImmunovant (NASDAQ:IMVT) Shares Gap Up to $31.50Immunovant (NASDAQ:IMVT) Shares Gap Up to $31.50March 13, 2024 | marketbeat.comImmunovant (NASDAQ:IMVT) Earns Buy Rating from Analysts at The Goldman Sachs GroupThe Goldman Sachs Group began coverage on shares of Immunovant in a report on Wednesday. They issued a "buy" rating and a $50.00 target price for the company.March 12, 2024 | finanznachrichten.deImmunovant Inc.: Immunovant Awarded U.S. Patent for IMVT-1402March 12, 2024 | globenewswire.comImmunovant Awarded U.S. Patent for IMVT-1402March 11, 2024 | finance.yahoo.comIMVT Jul 2024 30.000 callMarch 11, 2024 | finance.yahoo.comIMVT Mar 2024 40.000 callMarch 11, 2024 | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) is Alpine Global Management LLC's 3rd Largest PositionAlpine Global Management LLC trimmed its stake in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 13.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,252,474 shares of the company's stock aftMarch 10, 2024 | finance.yahoo.comIMVT Mar 2024 32.000 callMarch 10, 2024 | finance.yahoo.comIMVT Apr 2024 45.000 putMarch 10, 2024 | finance.yahoo.comIMVT Jan 2025 12.500 putMarch 10, 2024 | finance.yahoo.comIMVT Mar 2024 29.000 putMarch 9, 2024 | finance.yahoo.comIMVT Mar 2024 37.500 putMarch 9, 2024 | finance.yahoo.comIMVT Mar 2024 37.000 callMarch 8, 2024 | marketbeat.comAdage Capital Partners GP L.L.C. Takes $16.68 Million Position in Immunovant, Inc. (NASDAQ:IMVT)Adage Capital Partners GP L.L.C. acquired a new stake in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 434,500 shares of the company's stock, valued at approxi Get Immunovant News Delivered to You Automatically Sign up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter. Email Address Crypto Pioneer Says: “The last crypto bull market has begun.” (Ad)Right now, there’s over $6 trillion in potential investment money waiting on the sidelines. That means this crypto bull market has a lot more room to run before it comes close to being a bubble. Click here if you’d like to learn more about these five cryptos… IMVT Media Mentions By Week IMVT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMVT News Sentiment▼0.930.57▲Average Medical News Sentiment IMVT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMVT Articles This Week▼54▲IMVT Articles Average Week Get Immunovant News Delivered to You Automatically Sign up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: KRYS News Today IOVA News Today CRSP News Today SWTX News Today HALO News Today IMCR News Today IBRX News Today ACLX News Today UTZ News Today TWST News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMVT) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersDid Intel Just Dethrone Nvidia?Chaikin AnalyticsCharles Payne Demystifies OptionsUnstoppable ProsperityRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressElon to Transform U.S. Economy? Porter & CompanyThe only AI company you should be looking atBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunovant, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
